vialroom

#retatrutide 2026-04-02

Thursday63 messages14 participantstimes are UTC
Highlights from this day
  • customs_owl — anyone compared their Janoshik purity across two different KP lots 14:09
  • rezept_rolf — how slow is low and slow here, four weeks a step or longer 15:59
  • customs_owl — energy expenditure isnt something i could feel, though my sleep tracker disagreed with me 16:11
CO

anyone compared their Janoshik purity across two different KP lots

❤️2🤝5⚠️18

glucagon is the new bit

❤️5🙏7🧊1
SB

nobody should read my log as a plan, im recording what i did and thats all it is, ymmv

RR

is the phase 2 dosing anywhere near what people here run

⚠️5🙏4
GG

the honest position is this has less human evidence behind it than anything else discussed here

how do people square the research use only framing with logging their own use

RR

people insist on small steps because the side effects arrive faster than on the other two

RR

there is no long term safety data, phase 2 and an ongoing phase 3 programme is what exists

RR

back after 25 months, has anything actually been published since

😂16

held at 10 for 22 months and it never plateaued for me, which i cant explain, for what its worth

unrelated but anyone stayed at 12 for months rather than climbing

RR

i went up too fast, got a fortnight of nothing but nausea, and dropped back two steps

RR

triple agonist meaning GLP-1, GIP and glucagon, have i got that right

👀1
RR

came off at 32 weeks because my resting rate stayed elevated and i didnt like it

RR

does the glucagon arm explain the heart rate or is that unrelated

RR

stopped for 22 months and restarted at half my old dose, the ramp was easier second time

CO

i was wrong to call the heart rate a non issue last year, enough people logged it that i changed my mind

RR

i said 2 months ago that my heart rate had settled and it has stayed settled since

👍1
RR

how slow is low and slow here, four weeks a step or longer

baseline  58
wk 2      61
wk 4      64
wk 6      67
wk 8      66
wk 10     65   (held dose from wk 7)
📈13🤝3
CO

energy expenditure isnt something i could feel, though my sleep tracker disagreed with me

👍5❤️3🔥18

settled by month three

RR

buying this is a completely different risk conversation from the licensed compounds and that gets said too rarely

GV

triple agonist, GLP-1 and GIP and glucagon. the glucagon arm is the part with no long history

TN

does the energy expenditure claim show up as anything you can feel

CO

Medutest came back 99.4 on one lot and 98.1 on the next from the same FGP, both fine, i have it written down somewhere

GV

low and slow here means smaller steps than i ever used on tirzepatide, thats the received wisdom

GV

reconstituted the 2 vial to 8mg/ml specifically so i could take 12 without measuring crumbs

the half life supports weekly dosing and thats what ive done from the start

triple agonist yeah

GV

genuine question whats a sensible starting point, im seeing everything from 0.5 to 2

TN

im at 5 and the appetite effect is stronger than i expected, normal

no idea whether the heart rate settles for everyone, mine did and one log isnt data

GV

i log resting heart rate every morning because of this and its the one number i actually watch, not advice obviously

did the phase 2 result actually come in higher than the tirzepatide numbers

baseline  58
wk 2      61
wk 4      64
wk 6      67
wk 8      66
wk 10     65   (held dose from wk 7)
NS

phase 2 doses are published and theyre not far off what people here run, coincidence rather than plan

NS

research use only is on every vial and i treat it as exactly that, nobody here is prescribing

GG

ok so stepping in 1.7 increments instead of doubling is the only thing i would change if i started again

held mine ages

WN

the heart rate thing is real enough that i mention it whenever someone asks about starting

GA

anyone gone above 1 and what changed
reconstituted the 20 vial to 8mg/ml specifically so i could take 0.25 without measuring crumbs

TRIUMPH is the phase 3 programme, thats the name to search rather than the molecule

TF

the phase 2 weight result was larger than what the earlier agonists reported, in a smaller shorter trial

coming back to this is TRIUMPH the phase 3 programme